Video
Investigating suitable naïve versus pre-treated DME patients
Author(s):
Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.
Javier Zarranz-Ventura MD, PhD, FEBO, a vitreoretinal consultant at
Institut Clínic de Oftalmologia (ICOF), Hospital Clínic de Barcelona andInstitut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.
Related Videos
Related Content
Published: October 12th 2024 | Updated: October 11th 2024
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial
